Substance for restoring normal co-expression and interaction between the lox and nrage proteins

Abstract

The invention relates to the use of a substance for restoring normal co-expression and interaction between the LOX and NRAGE proteins. The invention relates in particular to the use of an effective amount of at least one substance that modulates the expression and/or activity of the LOX of SEQ ID NO: 1 and/or that modulates the expression and/or activity of the NRAGE of SEQ ID NO: 2 for modulating the interaction between the LOX and NRAGE proteins to regulate the balance between the cellular proliferation, differentiation and apoptosis, particularly in cases where the balance between these phenomena is disturbed, and especially in cases where the interaction between LOX and NRAGE is absent or altered. The invention makes it possible to treat skin ageing, lichen planus, graft-versus-host reaction (GVH), eczema, psoriasis and a cancer, particularly an epithelial cancer and more particularly a cutaneous epithelial cancer of basocellular or spinocellular type.

1 . A method for regulating balance between cellular proliferation, differentiation and apoptosis in epithelial cells, comprising applying a pharmaceutical or cosmetic composition onto an epidermis in need thereof, wherein said composition comprises an effective amount of:
 i) at least one active ingredient that modulates expression of the lysyl oxidase (LOX) having the amino acid sequence of SEQ ID NO: 1;   ii) at least one active ingredient that modulates expression of the NRAGE having the amino acid sequence of SEQ ID NO: 2; or   iii) a combination of the active ingredient of i) and the active ingredient of ii).   
     
     
         2 . The method of  claim 1 , wherein the epithelial cells are keratinocytes. 
     
     
         3 . The method of  claim 2 , wherein the active ingredient of i) increases the expression of the lysyl oxidase by about 50% in the keratinocytes. 
     
     
         4 . The method of  claim 2 , wherein the active ingredient of i) decreases the expression of the lysyl oxidase by about 50% in the keratinocytes. 
     
     
         5 . The method of  claim 2 , wherein the active ingredient of ii) increases the expression of the NRAGE by about 50% in the keratinocytes. 
     
     
         6 . The method of  claim 2 , wherein the active ingredient of ii) decreases the expression of the NRAGE by about 50% in the keratinocytes. 
     
     
         7 . A method of treating aging skin, comprising topically administering onto the skin an effective amount of at least one substance that modulates expression of LOX and/or NRAGE in the skin, said substance is selected from the group consisting of a  Sambucus nigra  extract, a  Humulus lupulus  extract, a  Ribes rubrum  extract, a  Cassia amara  extract, and an  Arbutus unedo  extract. 
     
     
         8 . A method for treating disorders relating to epidermal hypoproliferation, comprising topically applying an effective amount of a substance that stimulates expression of the LOX having the amino acid sequence of SEQ ID NO: 1 and at least one cosmetically or pharmaceutically acceptable excipient. 
     
     
         9 . The method of  claim 8 , wherein the substance is a Sambucus nigra extract, a  Humulus lupulus  extract, a  Ribes rubrum  extract, a  Cassia amara  extract, or an  Arbutus unedo  extract. 
     
     
         10 . The method of  claim 8 , further comprising topically applying an effective amount of a substance that inhibits expression of the NRAGE having the amino acid sequence of SEQ ID NO: 2. 
     
     
         11 . A cosmetic or pharmaceutical composition for modulating the interaction between LOX and NRAGE proteins in an epidermis, said composition comprising at least one substance selected from the group consisting of a Sambucus nigra extract, a  Humulus lupulus  extract, a  Ribes rubrum  extract, a  Cassia amara  extract, and an  Arbutus unedo  extract, and at least one cosmetically or pharmaceutically acceptable excipient.